Takeda Pharmaceutical/$TAK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Takeda Pharmaceutical

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Ticker

$TAK
Sector

Primary listing

NYSE

Employees

47,455

Headquarters

Tokyo, Japan

TAK Metrics

BasicAdvanced
$45B
25.84
$0.56
0.27
$0.54
3.82%

What the Analysts think about TAK

Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.

Bulls say / Bears say

Core revenue rose 7.4% at actual exchange rates and core operating profit increased 4.9% at constant exchange rates in FY2024, driven by strong performance in Growth & Launch Products (Takeda May 8, 2025 Press Release)
Takeda’s solid cash flow allowed for a proposed dividend increase from ¥196 to ¥200 per share for FY2025, demonstrating financial strength and ongoing commitment to shareholder returns (Takeda May 8, 2025 Press Release)
Positive Phase 3 results from two key studies of Oveporexton in Narcolepsy Type 1 indicate the strength of Takeda’s late-stage pipeline and long-term growth prospects (Takeda July 30, 2025 Press Release)
Generic competition for VYVANSE caused a 3.7% revenue decrease at constant exchange rates and an 11.9% drop in core operating profit in Q1 FY2025, highlighting ongoing margin pressures (Takeda July 30, 2025 Press Release)
Takeda expects to incur a ¥58.0 billion impairment charge in Q2 FY2025 related to its gamma delta T-cell therapy platform, highlighting costly R&D setbacks in cell therapy before exiting the segment (Reuters)
FY2025 management guidance points to core revenue and operating profit remaining flat overall, as spending on R&D and product launches increases, signaling little near-term growth in earnings (Takeda May 8, 2025 Press Release)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

TAK Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TAK

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs